Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12396
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWeinberg, Laurenceen
dc.contributor.authorTay, Sen
dc.contributor.authorAykanat, Ven
dc.contributor.authorSegal, Ren
dc.contributor.authorTan, C Oen
dc.contributor.authorPeyton, Philip Jen
dc.contributor.authorMcNicol, Larryen
dc.contributor.authorStory, David Aen
dc.date.accessioned2015-05-16T02:05:26Z-
dc.date.available2015-05-16T02:05:26Z-
dc.date.issued2014-09-01en
dc.identifier.citationAnaesthesia and Intensive Care; 42(5): 579-83en
dc.identifier.govdoc25233170en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12396en
dc.description.abstractEvidence-based choices of volatile agents can increase health cost efficiencies. In this pharmaco-economic study, we evaluated the trends and costs of volatile agent use in Australian public hospitals. The total number of volatile agent (isoflurane, sevoflurane and desflurane) bottles ordered and inflation-adjusted costs were collected from 65 Victorian public hospitals from 2005 to 2011. Environmental costs were measured through the 100-year global warming potential index as carbon dioxide equivalents. During this time period, the aggregate inflation-adjusted expenditure was $39,209,878. Time series analysis showed that bottles of isoflurane ordered decreased by 419/year (99% confidence interval (CI): -603 to -235); costs decreased by $56,017/year (99% CI: -$93,243 to -$18,791). Bottles of sevoflurane increased by 1,330/year (99% CI: 1141 to 1,519); costs decreased by $423,3573/year (99% CI: -$720,030 to -112,783). Bottles of desflurane increased by 726/year (99% CI: 288 to 1,164); costs increased by $171,578/year (99% CI: $136,951 to $206,205). The amount of calculated greenhouse gas emissions released into the atmosphere over this period was 37,000 tonnes of carbon dioxide equivalents, with isoflurane contributing 6%, sevoflurane 17%, and desflurane 77% of this total. In conclusion, isoflurane is no longer being used in the majority of Victorian public hospitals, with sevoflurane and desflurane remaining as the primary volatile agents, utilised respectively at a ratio of 2.2 to 1, and costs at 0.8 to 1.en
dc.language.isoenen
dc.subject.otheranaestheticsen
dc.subject.otherattentionen
dc.subject.othercost controlen
dc.subject.otherhealth expendituresen
dc.subject.otherinhalationen
dc.subject.otherAnesthetics, Inhalation.economicsen
dc.subject.otherAustraliaen
dc.subject.otherDrug Costsen
dc.subject.otherGlobal Warmingen
dc.subject.otherHospitals, Publicen
dc.subject.otherHumansen
dc.titleChanging patterns in volatile anaesthetic agent consumption over seven years in Victorian public hospitals.en
dc.typeJournal Articleen
dc.identifier.journaltitleAnaesthesia and Intensive Careen
dc.identifier.affiliationDepartment of Anaesthesia, Austin Hospital, Heidelberg, Victoria.en
dc.description.pages579-83en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25233170en
dc.type.austinJournal Articleen
local.name.researcherPeyton, Philip J
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
crisitem.author.deptAnaesthesia-
crisitem.author.deptAnaesthesia-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptAnaesthesia-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

36
checked on Mar 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.